Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Company Overview

Arrowhead Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development. Lead programs target chronic hepatitis B virus (HBV) infection (ARO-HBV), alpha-1 antitrypsin deficiency (ARO-AAT), cardiovascular disease through the silencing of apolipoprotein C-III (ARO-APOC3), and pulmonary diseases such as cystic fibrosis (ARO-ENaC). Arrowhead has entered collaboration agreements and licensing partnerships with major global pharmaceutical firms to accelerate the development and potential commercialization of its RNAi candidates.

Arrowhead conducts its research and early clinical studies primarily in the United States, with clinical trial sites and regulatory interactions spanning North America, Europe and Asia. The company’s manufacturing strategy combines internal capabilities with external contract development and manufacturing organizations (CDMOs) to support both preclinical work and advancing clinical-stage assets. This hybrid model is designed to optimize scalability as programs progress toward late-stage clinical testing.

Headquartered in Pasadena, California, Arrowhead is led by Chief Executive Officer Christopher Anzalone, who has guided the company through multiple platform refinements and strategic partnerships. The executive team comprises experienced drug developers and industry veterans dedicated to harnessing RNAi to address unmet medical needs. Arrowhead continues to expand its research collaborations and invest in next-generation delivery technologies to broaden its therapeutic reach.

Key Stats

• Today's Range: $34.91 to $36.10
• 50-Day Range: $16.06 to $37.50
• 52-Week Range: $9.57 to $39.42
• Volume: 1.83 million shs
• Average Volume: 2.34 million shs
• Market Capitalization: $4.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.14
• Consensus Rating: Moderate Buy

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

Arrowhead Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 173rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 4 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Arrowhead Pharmaceuticals has a consensus price target of $43.14, representing about 21.8% upside from its current price of $35.41.

Amount of Analyst Coverage

Arrowhead Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($3.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arrowhead Pharmaceuticals is -27.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arrowhead Pharmaceuticals is -27.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arrowhead Pharmaceuticals has a P/B Ratio of 22.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.58% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Arrowhead Pharmaceuticals has recently decreased by 6.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arrowhead Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.55

Percentage of Shares Shorted

8.58% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Arrowhead Pharmaceuticals has recently decreased by 6.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.48

News Sentiment

Arrowhead Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Arrowhead Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

32 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

MarketBeat Follows

2 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,725,000.00 in company stock.

Percentage Held by Insiders

Only 4.30% of the stock of Arrowhead Pharmaceuticals is held by insiders.

Percentage Held by Institutions

62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ARWR Stock Analysis - Frequently Asked Questions

How have ARWR shares performed this year?

Arrowhead Pharmaceuticals' stock was trading at $18.80 at the start of the year. Since then, ARWR stock has increased by 88.4% and is now trading at $35.41.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings results on Thursday, August, 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.32. The biotechnology company had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million.
Read the conference call transcript.

Who are Arrowhead Pharmaceuticals' major shareholders?

Top institutional shareholders of Arrowhead Pharmaceuticals include Assenagon Asset Management S.A. (0.28%), Voya Investment Management LLC (0.10%) and GAMMA Investing LLC. Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, William D Waddill, Adeoye Y Olukotun, Hongbo Lu and Victoria Vakiener.
View institutional ownership trends.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/11/2025
• Next Earnings (Estimated): 11/25/2025
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARWR
• CIK: 879407
• Web: www.arrowheadpharma.com
• Phone: (626) 304-3400
• Fax: 626-304-3401
• Employees: 400
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Arrowhead Pharmaceuticals: $43.14
• High Price Target: $80.00
• Low Price Target: $17.00
• Potential Upside/Downside: +21.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$599.49 million
• Net Margins: N/A
• Pretax Margin: -27.47%
• Return on Equity: -40.91%
• Return on Assets: -11.62%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 4.87
• Quick Ratio: 4.87

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 1,379.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: 22.99

Miscellaneous

• Outstanding Shares: 138,260,000
• Free Float: 132,313,000
• Market Cap: $4.90 billion
• Optionable: Optionable
• Beta: 1.13